In addition to overexpression of wild type EGFR, some tumors also exhibit activating mutant forms such as glioblastoma, where a variant called EGFRvIII has been reported (Gan et al., 2013) or non-small cell lung cancer (NSCLC) where mutations in the gene encoding the EGFR kinase domain (T790M) have been associated with tumor resistance (Ohashi et al., 2013). The gene discussed is EGFR; the disease is neoplasm.